Neurol. praxi. 2019;20(1):28-32 | DOI: 10.36290/neu.2019.087

Embolic stroke undetermined source

MUDr. Aleš Tomek, Ph.D., FESO, MUDr. Anna Olšerová
Neurologická klinika, 2. LF UK a FN Motol, Praha

Embolic stroke of undetermined source (ESUS) is a recent subtype of cryptogenic ischemic stroke. ESUS is defined as non-lacunar brain infarct without proximal arterial stenoses or cardioembolic sources with a clear indication for anticoagulation. Optimal secondary prevention in ESUS according to the current guidelines is antiplatelet treatment. The risk of recurrence is relatively high and therefore the new direct oral anticoagulants (DOAC) are tested in clinical trials. The article reviews recently published and ongoing studies of DOACs in ESUS patients. Based on available results seems reasonable that the ESUS concept should be refined into three or more distinct categories: ESUS with cardiopathy, ESUS with stenoses of large arteries bellow 50 % and other ESUS patients. The time of using ESUS concept in daily clinical practice has not yet come, but currently available data could help us guiding in the diagnostic algorithm in patients with undetermined cause of stroke.

Keywords: cryptogenic stroke, ESUS, ischemic stroke, DOAC

Published: March 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomek A, Olšerová A. Embolic stroke undetermined source. Neurol. praxi. 2019;20(1):28-32. doi: 10.36290/neu.2019.087.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment 1993; 24: 35-41. Go to original source...
    2. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC, Investigators SSCA. Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. Stroke 2017; 48: 2480-2487. Go to original source... Go to PubMed...
    3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, Investigators RLSCA. Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine 2009; 361: 1139-1151. Go to original source...
    4. Diener HC, Easton JD, Granger CB. Dabigatran versus acetylsalicylic acid for secondary stroke prevention in patients with embolic stroke of undetermined source: rationale, design, and baseline data from RE-SPECT ESUS. Poster presentation at 4th European Stroke Organization Conference. 2018. Go to original source...
    5. Geisler T, Mengel A, Ziemann U, Poli S. Management of embolic stroke of undetermined source (ESUS). Drugs 2018; 78(8): 823-831. Go to original source... Go to PubMed...
    6. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine 2013; 369: 2093-2104. Go to original source...
    7. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Mamdani M. Atrial fibrillation in patients with cryptogenic stroke. 2014; 370(26): 2467-2477.
    8. Granger CB, Alexander JH, Mcmurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, DIAZ R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2011; 365: 981-992. Go to original source... Go to PubMed...
    9. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke 2017; 48(8): 867-872. Go to original source... Go to PubMed...
    10. Hart RG, Diener HC, Coutts SB. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurology 2014; 13: 429-438. Go to original source... Go to PubMed...
    11. Hart RG, Sharma M, Mundl H. Rivaroxaban for Stroke Prevention after embolic stroke of undetermined source. New England Journal of Medicine 2018; 378(23): 2191-2201. Go to original source...
    12. Katsanos AH, Mavridis D, Parissis J, Deftereos S, Frogoudaki A, Vrettou AR, Ikonomidis I, Chondrogianni M, SAFOURIS A, Filippatou A, Voumvourakis K, Triantafyllou N, Ellul J, Karapanayiotides T, Giannopoulos S, Alexandrov AW, Alexandrov AV, Tsivgoulis G. Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis. Therapeutic Advances in Neurological Disorders 2016; 9: 359-368. Go to original source... Go to PubMed...
    13. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SCC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA, American heart association stroke councI, COC. ASN, Council on clinical cardiology, and council on peripheral vascular disease 2014. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a Guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-2236. Go to PubMed...
    14. Li L, Yiin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, Rothwell PM. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. The Lancet Neurology 2015; 14: 903-913. Go to original source... Go to PubMed...
    15. Longstreth WT, Kronmal RA, Thompson JLP, Christenson RH, Levine SR, Gross R, Brey RL, Buchsbaum R, Elkind MSV, Tirschwell DL, Seliger SL, Mohr JP, Defilippi CR. Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke 2013; 44: 714-719. Go to original source... Go to PubMed...
    16. Merkler AE, Gialdini G, Murthy SB, Salehi Omran S, Moya A, Lerario MP, Kamel H. Association between troponin levels and embolic stroke of undetermined source. Journal of the American Heart Association 2017; 6(9): 1-7. Go to original source... Go to PubMed...
    17. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New England Journal of Medicine 2001; 345(20): 1444-1451. Go to original source... Go to PubMed...
    18. Nouh A, Hussain M, Mehta T, Yaghi S. Embolic strokes of unknown source and cryptogenic stroke: implications in clinical Practice. Frontiers in Neurology 2016; 7: 1-16. Go to original source... Go to PubMed...
    19. Ntaios G, Lip GYH, Vemmos K, Koroboki E, Manios E, Vemmou A, Papavasileiou V. Age - and sex-specific analysis of patients with embolic stroke of undetermined source. Neurology 2017; 86(6): 532-539. Go to original source... Go to PubMed...
    20. Ntaios G, Papavasileiou V, Milionis H, Makaritsis K, Vemmou A, Koroboki E, Vemmos K. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke 2015; 46(8): 2086-2093. Go to original source... Go to PubMed...
    21. Ntaios G, Vemmos K, Lip GYH, Koroboki E, Manios E, Vemmou A, Papavasileiou V. Risk stratification for recurrence and mortality in embolic stroke of undetermined source. Stroke, 2016; 47(9): 2278-2285. Go to original source... Go to PubMed...
    22. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine 2011; 365(10): 883-891. Go to original source... Go to PubMed...
    23. Renna R, Pilato F, Profice P, Della Marca G, Broccolini A, Morosetti R, Frisullo G, Rossi E. Risk factor and etiology analysis of ischemic stroke in young adult patients. J Stroke Cerebrovasc Dis 2014; 23: e221-227. Go to original source... Go to PubMed...
    24. Sacco RL, Prabhakaran S, Thompson JLP. Murphy A, Sciacca RR, Levin B, Mohr JP. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovascular Diseases 2006; 22(1): 4-12. Go to original source... Go to PubMed...
    25. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Brachmann J. Cryptogenic stroke and underlying atrial fibrillation. New England Journal of Medicine 2014; 370(26): 2478-2486. Go to original source... Go to PubMed...
    26. Saver JL. Cryptogenic Stroke. N Engl J Med 2016; 374: 2065-2074. Go to original source... Go to PubMed...
    27. Spence J. Cardioembolic stroke: everything has changed. Stroke and Vascular Neurology 2018; 3: 76-83. Go to original source... Go to PubMed...
    28. Sporns PB, Hanning U, Schwindt W. Ischemic stroke: what does the histological composition tell us about the origin of the thrombus? Stroke 2017; 48 (8): 2206-2210. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.